Advertisement
Advertisement
December 3, 2025
PRINCIPIIS FIH Study Begins for Angiolutions A3 Shield System in Early Stage AAA
December 3, 2025—Angiolutions announced that the first patient has been treated in a first-in-human (FIH) study evaluating the safety and effectiveness of the company’s investigational A3 Shield system.
According to the company, the PRINCIPIIS FIH trial is designed to evaluate the A3 Shield as an early interventional option for patients with small abdominal aortic aneurysms (AAAs). The trial is being conducted at several centers in Tashkent, Uzbekistan.
“Treating the first patient in PRINCIPIIS-FIH is an important step toward offering an earlier, less invasive option to patients with AAAs who are currently managed by surveillance alone,” commented Professor Hubert Schelzig, MD, in the company’s press release. “By targeting a root biomechanical driver of AAA progression, the A3 Shield system aims to reduce the risk of future rupture and limit the need for complex aortic repair. The data from PRINCIPIIS FIH will help us determine how this concept can be translated into routine clinical practice.”
Prof. Schelzig is Director of the Clinic for Vascular and Endovascular Surgery at the University Hospital Düsseldorf in Düsseldorf, Germany, and a member of the Medical Board at Angiolutions.
Advertisement
Advertisement
